Search results
Showing 91 to 105 of 109 results for paclitaxel
The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)
Discontinued [GID-MT517]
Evidence-based recommendations on tucatinib (TUKYSA) for HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies.
This guidance has been replaced by NICE guideline CG24 [Replaced by NICE guideline CG121].
This guidance has been updated and replaced by NICE technology appraisal guidance 770.
This guidance has been updated and replaced by NICE technology appraisal guidance 476.
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)
Evidence-based recommendations on cabazitaxel (Jevtana) for people with prostate cancer that has come back after it was treated with docetaxel.
This guidance has been updated and replaced by NICE technology appraisal guidance 389.
Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults.
Show all sections
Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer in adults who have had trastuzumab and a taxane.
NICE has developed a medtech innovation briefing (MIB) on plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer .
Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic
The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Avelumab not recommended as a maintenance treatment of urothelial cancer
NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of urothelial cancer after platinum-based chemotherapy.